These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 33620160

  • 1. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A, Bener A, Caglayan B, Tangri R, Mitsakakis N.
    Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
    [Abstract] [Full Text] [Related]

  • 2. Phase II oncology trials: let's be positive.
    Ratain MJ.
    Clin Cancer Res; 2005 Aug 15; 11(16):5661-2. PubMed ID: 16115898
    [No Abstract] [Full Text] [Related]

  • 3. The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.
    Mohamed L, Manjrekar S, Ng DP, Walsh A, Lopes G, Parker JL.
    Oncologist; 2022 Oct 01; 27(10):849-856. PubMed ID: 35993585
    [Abstract] [Full Text] [Related]

  • 4. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J, Baral S, Tu D, Nomikos D, Seymour L.
    Clin Cancer Res; 2005 Aug 15; 11(16):5928-34. PubMed ID: 16115935
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb 15; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD.
    Z Evid Fortbild Qual Gesundhwes; 2012 Feb 15; 106(1):11-22. PubMed ID: 22325103
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2024406. PubMed ID: 33170262
    [Abstract] [Full Text] [Related]

  • 13. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Expert Rev Mol Diagn; 2017 Oct 02; 17(10):933-942. PubMed ID: 28838271
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E, Asada R, Lu Y, Ito-Ihara T, Grimes KV.
    Clin Ther; 2020 Feb 02; 42(2):305-320.e0. PubMed ID: 32008723
    [Abstract] [Full Text] [Related]

  • 17. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.
    Cancer J; 2009 Feb 02; 15(5):406-20. PubMed ID: 19826361
    [Abstract] [Full Text] [Related]

  • 18. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB, Carvalho Oliveira LJ, Jardim DL.
    Expert Rev Mol Diagn; 2020 Jun 02; 20(6):611-618. PubMed ID: 31903795
    [Abstract] [Full Text] [Related]

  • 19. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R.
    Lancet Oncol; 2011 Aug 02; 12(8):795-805. PubMed ID: 21782507
    [Abstract] [Full Text] [Related]

  • 20. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR.
    Clin Pharmacol Ther; 2015 May 02; 97(5):488-91. PubMed ID: 25676724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.